Edition:
United Kingdom

Carl O'Donnell

Eli Lilly strikes optimistic tone on COVID-19 therapy after trial failure

27 Oct 2020

Eli Lilly and Co on Tuesday aimed to ease investor concerns about its COVID-19 antibody treatment after a trial of the therapy failed to show a benefit in hospitalized patients. | Video

AstraZeneca resumes U.S. COVID-19 vaccine trial and next week J&J prepares to do same

24 Oct 2020

AstraZeneca Plc has resumed the U.S. trial of its experimental COVID-19 vaccine after approval by regulators, and Johnson & Johnson is preparing to resume its trial on Monday or Tuesday, the companies said on Friday. | Video

U.S. likely to have enough COVID-19 vaccines for all vulnerable Americans by year end - official

22 Oct 2020

The United States is likely to have enough safe and effective COVID-19 vaccines available to inoculate the most vulnerable Americans by the end of 2020, Health and Human Services Secretary Alex Azar said on Wednesday.

U.S. likely to have enough COVID-19 vaccines for all vulnerable Americans by year end - official

22 Oct 2020

The United States is likely to have enough safe and effective COVID-19 vaccines available to inoculate the most vulnerable Americans by the end of 2020, Health and Human Services Secretary Alex Azar said on Wednesday. | Video

U.S. likely to have enough COVID-19 vaccines for all vulnerable Americans by year end -official

21 Oct 2020

Oct 21 The United States is likely to have enough safe and effective COVID-19 vaccines available to inoculate the most vulnerable Americans by the end of 2020, Health and Human Services Secretary Alex Azar said on Wednesday.

Abbott says COVID-19 test demand to grow in 2021

21 Oct 2020

Abbott Laboratories said it expects demand for its COVID-19 tests to grow in 2021 even if a vaccine is developed and for the business to eventually stabilize into a lucrative new franchise.

Explainer: When will COVID-19 vaccines be generally available in the United States?

16 Oct 2020

U.S. President Donald Trump and the head of the Centers for Disease Control and Prevention (CDC) have disagreed about when a COVID-19 vaccine would become widely available. Trump has said enough vaccine would be available for every American by April, while the CDC director said vaccines were likely to reach the general public around mid-2021, an assessment more in line with most experts.

Q&A: Where are we in the COVID-19 vaccine race?

16 Oct 2020

NEW YORK Drugmakers and research centers around the world are working on COVID-19 vaccines, with large global trials of several of the candidates involving tens of thousands of participants well underway.

World News